Literature DB >> 14584752

Thromboembolic risk factors in patients undergoing kidney transplant: implication of abnormally short activated partial thromboplastin time.

Nabil G Guirguis1, Chad Eicher, Lynette Hock, James Lynch, Vicki D Graham, P R Rajagopalan, Amal Guirguis, John Lazarchick.   

Abstract

This study was designed to examine the relationship of short activated partial thromboplastin time (aPTT) and prothrombin time (PT) to the incidence of thromboembolic events, hereditary and acquired coagulation defects associated with an increased risk of thrombosis, or cardiovascular diseases in patients undergoing renal transplantation. The prevalence of these conditions in our patients (n = 436) was 55%. Forty-two percent of the patients had short aPTT or PT. Multivariate analysis revealed that patients with short aPTT have an odds ratio (OR) = 2.15, 95% Confidence Interval (CI) (1.27-3.64) (p = 0.0042), and for patients with short PT, an OR = 2.01, 95% CI (0.99-4.08) (p = 0.052). Our study also suggests that other risk factors, including non-white ethnicity (98% blacks), OR = 1.64, 95% CI (1.01-2.67) (p = 0.047), diabetes mellitus, OR = 2.62, 95% CI (1.11-6.18) (P = 0.028), and autosomal dominant polycystic kidney disease (ADPKD) (p < 0.0001). Short aPTT results, or probably short PT results, pre- or post-transplantation may be associated with increased risks for thromboembolism.

Entities:  

Mesh:

Year:  2003        PMID: 14584752

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  2 in total

1.  Evaluation of Heparin Anticoagulation Protocols in Post-Renal Transplant Recipients (EHAP-PoRT Study).

Authors:  Joan Chung Yan Ng; Marianna Leung; David Landsberg
Journal:  Can J Hosp Pharm       Date:  2016-04-29

2.  Chronometric vs. Structural Hypercoagulability.

Authors:  Carmen Delianu; Mihaela Moscalu; Loredana Liliana Hurjui; Claudia Cristina Tărniceriu; Oana-Viola Bădulescu; Ludmila Lozneanu; Ion Hurjui; Ancuta Goriuc; Zinovia Surlari; Liliana Foia
Journal:  Medicina (Kaunas)       Date:  2020-12-28       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.